679 episodes
ReachMD CME ReachMD
-
- Science
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
-
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
CME credits: 0.25
Valid until: 22-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/strategic-excellence-mastering-the-expanding-attr-cm-therapeutic-landscape-in-pharmacy-practice/18124/
Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.
= -
Accurate Staging and Determining Resectability in NSCLC
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities. -
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/chemoradiotherapy-toxicities-how-do-they-impact-starting-immunotherapy/24389/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities. -
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities. -
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-following-scrt-vs-rt-only-in-stage-iii-nsclc/24388/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities. -
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-with-oncogenic-drivers/24391/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Top Podcasts In Science